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INTRODUCTION
Benign breast disease deserves attention because of
its high prevalence, its impact on women's quality of
life, and, for some histologic types, its cancerous po-
tential. Identification of risk factors for benign breast
disease could improve our understanding of its etiol-
ogy and pathogenesis and help to define preventive
strategies.
Benign breast disease has been extensively studied,
and this wealth of literature warrants periodic reeval-
uation. This paper both updates and extends a previous
review by Ernster (1) by summarizing accumulated
information on the relation of benign breast disease to
smoking, methylxanthines, and diet that was not cov-
ered in that earlier review. It does not, however, in-
clude a section on the relation between benign breast
disease and breast cancer, a topic recently reviewed by
Bodian (2). We have also attempted to consolidate the
wide range of terms used to describe the histologic
manifestations of this disease.
METHODS
We began by conducting a MEDLEME® search us-
ing the keywords "benign breast disease," "epidemi-
ology," and "risk factors." The bibliographies of re-
trieved articles were then used to identify other
references.
All autopsy and cohort studies that we were able to
identify were used to estimate the frequency of benign
breast disease.
We concentrated our review of risk factors on stud-
ies that used a histologic definition of benign breast
disease. Studies that relied only on anamnestic (3-7)
or clinical (8) definitions of benign breast disease,
intervention trials in which there were no controls
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(9-11), and studies for which incomplete information
about methodology was provided (12, 13) were ex-
cluded from our analysis. The remaining studies were
then grouped according to their methodological design
into three categories: 1) case-control studies with hos-
pital controls, 2) case-control studies with population
controls, and 3) cohort and nested case-control series.
Each risk factor was then studied separately. Included
studies and their salient design characteristics are
listed in table 1.
Breast morphology and development
Breast development and related terminology is pre-
sented in figure 1. Briefly, 1) the mammary gland
develops in the embryo from an invagination of the
superficial ectoderm which forms elementary ducts in
the connective tissue; 2) before puberty, the ducts
grow and divide in a dichotomous way; and 3) lobule
formation occurs after menarche and increases with
age up to about the age of 25 years (14, 15). Epithelial
and stromal proliferation and regression occur regu-
larly with menstruation, but complete differentiation
with maximal development of lobular tissue takes
place only through pregnancy and lactation. Accord-
ing to Hughes (16), regression occurs in a patchy
pattern after pregnancy; involution of lobules and
ducts starts at about the age of 35 years.
Russo and Russo (17) demonstrated that at the cel-
lular level, development of the human breast was
related not only to age but also to the reproductive
history of the host. Russo et al. (18) then showed that
the level of DNA synthesis reflecting cell proliferation
decreased with age, but that parity had an even greater
influence on its diminution because DNA synthesis in
the human breast epithelium was significantly lower
after the structures were differentiated by pregnancy
(high in intralobular terminal ducts, decreasing in al-
veoli and ducts). Going et al. (19) and Meyer (20)
further demonstrated that cell proliferation in breast
lobular epithelium was higher during the second half
of the menstrual cycle, even when artificially regu-
lated by oral contraceptives.
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nipple
a) at birth: elementary ducts
terminal end buds
b) before puberty: duct growth and dichotomous division
ilar terminal duct
"ductule or acini
:tralobular terminal duct
lobule
terminal ductal lobular unit
c) after first menses: lobule formation
FIGURE 1. Breast development and terminology. (Adapted from Russo et al. (14) and Wellings (15).)
Definition of benign breast disease
The study of benign breast disease is difficult be-
cause of the lack of clear-cut clinical and histopatho-
logic separation between physiologic and pathologic
changes in the breast. There are numerous definitions
and classifications, but two major ones dominate the
epidemiologic literature, fibroadenoma and fibrocystic
breast disease; more recent reports have introduced the
concept of benign epithelial proliferative disorders.
Fibroadenomas are benign tumors. Macroscopi-
cally, they are pseudoencapsulated and sharply delim-
ited; microscopically, they have both an epithelial and
a stromal component. They appear to result from hy-
perplasia and distortion originating in a single lobule;
the epithelial cells are normal, whereas connective
tissue from the stromal component contains abnormal
cells found only in fibroadenomas (21). Fibrocystic
breast disease, in contrast to fibroadenoma, is an ill-
defined diagnosis used by both clinicians and pathol-
ogists. Clinically, it is "a condition in which there are
palpable lumps in the breast, usually associated with
pain and tenderness, that fluctuates with the menstrual
cycle and that becomes progressively worse until
menopause" (22, p. 1010). Fibrocystic breast disease
is discussed in the literature under many names, in-
cluding chronic cystic mastitis, cystic disease, cystic
hyperplasia, epithelial dysplasia, and mastopathia.
Histologically, lesions of fibrocystic breast disease are
of epithelial origin. Microscopically, they are usually
micro- and macrocysts which may (or may not) be
associated with apocrine epithelium, epitheliosis, ad-
enosis, papillomatosis, and/or solitary and multiple
papillomas. These terms are clearly defined by Schnitt
and Conolly (21). Briefly, cysts are fluid-filled struc-
tures that are round-to-ovoid in shape and that vary in
size from microscopic to grossly evident. Gross cysts,
as defined by Haagensen (23), are derived from the
terminal ductal lobular unit and are large enough to
produce palpable masses. The epithelium usually con-
sists of an inner epithelial layer and an outer myoepi-
thelial layer. Cysts can be associated with 1) metapla-
sia, in which normal epithelium evolves into apocrine
epithelium, the type of epithelium that lines apocrine
glands in the vulva, axilla, and eyelids, and is charac-
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TABLE 1. Characteristics of studies of fibrocystic breast disease and fibroadenomas
Study
(reference no.)
Location
and
year
Study design Incident
cases
Cases
Age Benign breast
Controls Menopause range disease
(years) definition
I
p
N>
CD(O
Baghurst and Rohan* (105)
BCDSPt,* (121)
BCDSPJ (96)
Berkowltz et al.§ (85)
Berkowltz et al.§ (86)
Berkowltz et al.§ (70)
Berkowltz et al.§ (64)
Berkowltz et al.§ (94)
Boyle et al.§ (66)
Bright et al. (77)
Brlnton et al. (51)
Canny et al.§ (53)
Cole et al. (47)
Duffy et al. (73)
Australia, 1995
United States,
1973
United States,
1974
United States,
1984
United States,
1984
United States,
1985
United States,
1985
United States,
1985
United States,
1984
United States,
1989
United Kingdom,
1981
United States,
1988
United States,
1978
Scotland, 1983
Case-control, with
one hospital and
one population
control
Hospital-based
case-control
Hospital-based
case-control
Hospital-based
case-control
Hospital-based
case-control
Hospital-based
case-control
Hospital-based
case-control
Hospital-based
case-control
Hospital-based
case-control
Hospital-based
case-control
Cohort nested
case-control
Hospital-based
case-control
Population-based
case-control
Hospital-based
case-control
Yes
Yes
Yes
NAf
NA
NA
NA
NA
NA
Yes
Yes?
NA
Yes
No
First breast biopsy with
epithelial proliferation
in a major laboratory
(n = 354)
Discharge diagnosis of
benign breast disease
(n = 98)
Discharge diagnosis of
benign breast disease
In 24 hospitals (n = 52)
Pathology register of five
hospitals (n = 633)
Pathology register of five
hospitals (n = 590)
Pathology register of five
hospitals (n = 590)
Pathology register of five
hospitals (n = 884)
Pathology register of five
hospitals (n= 143)
Pathology register of five
hospitals (n = 634)
Incident cases during the
year after a diagnostic
mammography (n= 172)
From the >17,000 women of
the Oxford Family
Planning Association
Contraceptive Study
(n = 686)
Pathology register of five
hospitals (n = 251)
Pathology registers of
25 hospitals (n = 678)
Discharge diagnosis from
surgery (n = 188)
First breast biopsy without
epithelial proliferation
(n= 189); matched from
the electoral roll
(n = 354)
Acute illness or elective
surgery (n = 842)
Acute illness or elective
surgery (n = 774)
Surgery (n = 1,062)
Surgery (n= 1,018)
Surgery (n = 1,018)
Surgery (n = 1,077)
Surgery (n = 355)
Surgery (n = 1,066)
Screening or baseline
mammography (n = 134)
Matched (n = 686)
Surgery (n = 1,081)
Resident list, group-matched
for age (n= 1,807)
Invited In the Breast
Screening Clinic, selected
in general practlcer lists
(n = 2,213)
All
Pre-
menopause
Post-
menopause
All
All
All
All
Post-
menopause
All
All
Pre-
menopause
All
All
All
18-75
20-44
45-69
20-74
20-74
20-74
20-74
<74
20-74
>20
25-39
at
recruitment
20-74
>20
40-54
Biopsy (reviewed), classified
by degree of proliferation
or atypia
Biopsy, fibrocystic breast
disease and
fibroadenoma
Biopsy, fibrocystic breast
disease and
fibroadenoma
Biopsy (reviewed), fibrocystic
breast disease
Biopsy (reviewed), fibrocystic
breast disease classified
by degree of proliferation
or atypia
Biopsy (reviewed), Itorocystic
breast disease classified
by degree of proliferation
or atypia
Biopsy (reviewed), Itorocystic
breast disease and
fibroadenoma
Biopsy (reviewed), fibrocystic
breast disease
Biopsy (reviewed), classified
by degree of proliferation
or atypia
Biopsy (reviewed), fibrocystic
breast disease and
fibroadenoma
Pathology register, hospital
records, fbrocystlc
breast disease and
fibroadenoma
Biopsy (reviewed),
fibroadenoma
Pathology register, fibrocystic
breast disease and
fibroadenoma
"Surgically confirmed",
fibrocystic breast disease
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Ernster et al. (122)
Fasal and Paffenbarger
(75)
Fleming et al. (49)
Franceschi et al.H (63)
Hislop and Elwood (52)
Hislop et al. (79)
Hsieh et al.# (83)
Hsieh et al.# (72)
Ingram etal.** (103)
Ingram et al.** (78)
Jick et al. (50)
Kelsey et al . t t (57)
Kelsey et al . t t (62)
La Vecchia et al.H (67)
Lawsonetal.t (123)
United States,
1982
United States,
1975
Australia, 1982
Italy, 1984
Canada, 1981
Canada, 1990
United States,
1984
United States,
1984
Australia, 1991
Australia, 1989
United States,
1988
United States,
1974
United States,
1978
Italy, 1985
United States,
1981
Randomized trial
Hospital-based
case-control
Population-based
case series
Hospital-based
case-control
Cohort
Screening-based
case-control
Cohort nested
case-control
Cohort nested
case-control
Population-based
case-control
Population-based
case-control
Cohort
Hospital-based
case-control
Hospital-based
case-control
Hospital-based
case-control
Hospital-based
case-control
No
No
NA
Yes
No
Yes?
Yes
No
NA
NA
Yes
NA
Yes
Yes
Breast Screening Clinic,
with clinical benign
breast disease, instructed
to stop caffeine
consumption (n = 72)
19 hospitals (n= 446)
Pathology, hospital and
cancer registers
(n= 1,283)
Referred for biopsy in a
second-level hospital
(n = 288)
Symptomatic mastopathies—
107biopsied, of 1,374
nursing students (n =
215)
From the National Breast
Screening Study (n =
398)
(n = 232)
(n = 218)
Pathology reports (n = 186)
Pathology reports (n = 192)
From the "Group Health
Cooperative" (n = 142)
(n = 384)
(n = 366)
Referred for biopsy in a
second-level hospital
(Milan Tumor Institute)
(n = 288)
Discharge diagnosis
(n = 210)
Breast Screening Clinic,
with clinical benign
breast disease, no
instructions (n = 68)
Matched, medical wards
(n=433); matched,
surgical wards (n = 439)
Acute illness except
oncologic, gynecologic,
or digestive trouble in
three hospitals (n = 285)
From the National Breast
Screening Study (n =
398)
(n= 1,000)
(n = 928)
Matched, electoral rolls
(n = 209)
Electoral rolls (n = 211)
Matched, surgery (n = 384)
Matched, surgery (n = 366)
Acute illness except
oncologic, gynecologic,
or digestive In three
hospitals (n = 285);
screening for cervical
cancer at Milan Tumor
Institute (n = 291)
Matched 3:1 acute illness
or surgery (n = 630)
All
All
All
All
All
All
All
All
All
All
Post-
menopause
Pre-
menopause
Pre-
menopause
All
All
19-66 Clinical examination, fibro-
cystic breast disease
and fibroadenoma
<50 Biopsy (reviewed), fibrocystic
breast disease and fibro-
adenoma
Pathology register, fibrocystic
breast disease and
fibroadenoma
17-64 Biopsy (reviewed), fibrocystic
breast disease and
fibroadenoma
Pathology register,
anamnestic, fibrocystic
breast disease and
fibroadenoma
40-59 Biopsy (reviewed), classified
by degree of proliferation
or atypia
Biopsy (reviewed), classified
by degree of proliferation
or atypia
Biopsy (reviewed), classified
by degree of proliferation
or atypia
19-72 Biopsy (reviewed), classified
by degree of proliferation
or atypia
19-72 Biopsy (reviewed) classified
by degree of proliferation
or atypia
50-64 Pathology register, fibrocystic
breast disease
20-44 Pathology register, fibrocystic
breast disease and
fibroadenoma
20-44 Biopsy (reviewed), fibrocystic
breast disease and
fibroadenoma
17-64 Pathology register, fibrocystic
breast disease and
fibroadenoma
Hospital records, fibrocystic
breast disease
Table 1 continues
TABLE 1. Continued
Study
(reference no.)
Location
and
year
Study design Incident
cases
Cases Controls Menopause
Age
range
(years)
Benign breast
disease
definition
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Lees et al. (82)
Lees et al. (82)
LiVoIsi et al. t t (84)
London etal. (71)
Lubineta l . t t ( iH)
Lubin et a l . i t (102)
Marshall etal. (124)
Nomura et al. (56, 125)
Ory et al. (46)
Parazzlni et al.H (60)
Parazzini et al.1l (65)
Pastides etal.§§ (81)
Pastides et al.§§ (69)
Pastides et al.§§ (95)
Canada, 1978
Canada, 1978
United States,
1978
United States,
1992
Israel, 1985
Israel, 1989
United States,
1982
United States,
1976, 1977
United States,
1976
Italy, 1984
Italy, 1991
United States,
1983
United States,
1985
United States,
1987
Hospital-based
case-control
Hospital-based
case-control
Hospital-based
case-control
Hospital-based
case-control
Case-control with
one hospital and
one population
control
Case-control with one
hospital and one
population
control
Hospital-based
case-control
Population-based
case-control
Cohort
Hospital-based
case-control
Hospital-based
case-control
Hospital-based
case-control
Hospital-based
case-control
Hospital-based
case-control
No
No
NA
NA
No
No
NA
No
Yes
Yes
Yes
NA
No
NA
Referred in a diagnostic
breast clinic, biopsied
(n = 692)
Referred in a diagnostic
breast clinic, biopsied
(n = 692)
(n = 205)
Evaluated for breast
problems, biopsy of
proliferative disease
(n=173)
Surgery and pathology
records (n = 854)
Surgery and pathology
records (n = 854)
Hospital discharge
diagnosis (n = 323)
Pathology register (n = 320)
From 67,500 (n = 582)
Referred for biopsy in a
second-level hospital
(n = 288)
Referred for biopsy in a
second-level hospital
(n = 288)
(n=125)
(n = 255)
(n = 255)
Matched 3:1 acute illness
or surgery (n = 630)
Referred in a diagnostic
breast clinic, not
biopsied (n = 548)
Matched, surgery (n = 205)
Evaluated for breast problem,
with biopsy of nonpro-
liferative disease or
no biopsy (n = 403)
Surgery (n = 755); neighbor-
hood (electoral rolls)
{n = 723)
Surgery (n = 755); neighbor-
hood (electoral rolls)
(n=723)
Non-neoplastic diseases
except breast (n =
1,458)
Matched, from the census
list (n = 320)
Acute illness except
oncologic, gynecologic,
or digestive trouble in
three hospitals (n = 285)
Screening for cervical cancer
at the Milan Tumor
Institute (n= 291)
Matched, surgery,
orthopedics, and ear,
nose, and throat (n= 129)
Surgery, orthopedics, and ear,
nose, and throat (n = 790)
Surgery, orthopedics, and ear,
nose, and throat {n = 787)
All
All
Pre-
menopause
Post-
menopause
All
All
All
All
All
All
All
All
All
All
20-44
55-68
20-49
17-64
17-64
20-44
20-74
20-74
Hospital records, fibrocystic
breast disease
Pathology register, fibrocystic
breast disease and
fibroadenoma
Biopsy (reviewed), classified
by degree of proliferation
or atypia
Pathology register, classified
by degree of proliferation
or atypia
Biopsy (reviewed), classified
by degree of proliferation
or atypia
Biopsy (reviewed), classified
by degree of proliferation
or atypia
Hospital records, fibrocystic
breast disease
Pathology register, fibrocystic
breast disease and
fibroadenoma
Pathology register, fibrocystic
breast disease and
fibroadenoma
Pathology register, fibrocystic
breast disease and
fibroadenoma
Pathology register, fibrocystic
breast disease and
fibroadenoma
Biopsy (reviewed), classified
by degree of proliferation
or atypia
Biopsy (reviewed), classified
by degree of proliferation
or atypia
Biopsy (reviewed), classified
by degree of proliferation
or atypia
13
o'
$
Vol
.
19
.
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§
Ravnihar et al. (61)
Rohan etal.* (76,98, 101,
112)
Sartwell et al. (58)
Sartwell et al. (59)
Schalrer et al. (68)
Simard et al.iffl (8)
Simard et al.ffll (74)
Soini et al. (48)
Trapido et al. (55)
Vessey et al. (80)
Vobecky et al.ffll (104)
Yu et al.* (54)
Yugoslavia, 1979
Australia, 1989,
1990
United States,
1973
United States,
1978
United States,
1986
Canada, 1993
Canada, 1990
Finland, 1981
United States,
1984
United States,
1971
Canada, 1993
Australia, 1992
Hospital-based
case-control
Case-control with
one hospital and
one population
control
Hospital-based
case-control
Hospital-based
case-control
Screening-based
case-control
Screening-based
case-control
Screening-based
case-control
Population-based
case-control
Screening-based
case-control
Hospital-based
case-control
Screening-based
case-control
Case-control with one
hospital and one
population control
Yes (n = 497)
Yes First breast biopsy with
epithelial proliferation
in a major laboratory
(n = 383)
Yes (n = 416)
NA (n = 938)
NA From >280,000 women in
BCDDP(n= 1,569)
No From 6,232 women in the
National Breast
Screening Study (n =
334)
NA From 9,089 women in the
National Breast
Screening Study (n =
340)
NA Pathology registers (n = 422)
NA From >280,000 women in
BCDDP(f)=929)
NA (n=166)
No From 9,089 women in the
National Breast Screening
Study (n= 334)
Yes First breast biopsy with fibro-
adenoma in a major
laboratory (n = 117)
Matched, dermatology
ophthalmology, surgery
(n = 497)
First breast biopsy without
epithelial proliferation
(n= 192); matched from
the electoral roll (n = 383)
Matched, all wards except
gynecology and urology
(n = 416)
Matched, all wards except
gynecology and
psychiatry (n = 938)
Not referred for surgery
(n= 1,846)
Matched for age (n = 340)
Matched for age (n = 343)
Matched for age, population
registry (n = 422)
Not referred for evaluation or
biopsy (n = 846)
Medicine or surgery (n = 166)
Matched for age (n = 340)
First breast biopsy without
epithelial proliferation (n
= 192); matched from the
electoral roll (n= 117)
All
All
All
All
All
All
All
All
Post-
menopause
Pre-
menopause
All
All
15-64
18-75
20-70
20-69
40-59
at entry
40-59
at entry
16-39
40-59
at entry
18-75
Biopsy (reviewed), fibrocystic
breast disease and
fibroadenoma
Biopsy (reviewed), classified
by degree of proliferation
or atypla
Pathology register, fibrocystic
breast disease and
fibroadenoma
Pathology register, fibrocystic
breast disease and
fibroadenoma
Biopsy (reviewed), classified
by degree of proliferation
or atypia
Clinical examination,
fibrocystic breast disease
Pathology register plus
hospital records,
fibrocystic breast disease
Biopsy (reviewed), classified
by degree of proliferation
or atypla
Pathology register, fibrocystic
breast disease and
fibroadenoma
Biopsy (reviewed), fibrocystic
breast disease and
fibroadenoma
Pathology register plus
clinical examination,
fibrocystic breast disease
Biopsy (reviewed),
fibroadenoma
* The following references use data from the same study (54, 76, 98,101,105,112).
t Abbreviations: BCDSP, Boston Collaborative Drug Surveillance Program; NA, not applicable.
t The following references use data from the same study (96,121,123).
§ The following references use data from the same study (53,64, 66,70,85,86, 94).
1) The following references use data from the same study (60, 63, 65, 67).
# The following references use data from the same study (72, 83).
•• The following references use data from the same study (78,103).
f t The following references use data from the same study (57, 62, 84).
it The following references use data from the same study (102,111).
§§ The following references use data from the same study (69, 81, 95).
HH The following references use data from the same study (8, 74,104).
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terized by granular eosinophilic cytoplasm and apical
cytoplasmic protrusions, or 2) hyperplasia, which can
produce epitheliosis and adenosis. In epitheliosis (also
termed ductal or lobular hyperplasia), one cell type
proliferates within the existing ductal or lobular struc-
ture. Adenosis is the development of new lobular or
ductal structures, with proliferation of epithelial and
myoepithelial cells. In sclerosing adenosis, the myo-
epithelial component predominates. The term paplllo-
matosls is confusing because it is used both for epi-
theliosis (by Foote and Stewart (24) and by Haagensen
(23)) and for multiple microscopic or macroscopic
ductal papillomas, distinguished by vascular stalks.
The concept of benign epithelial prollferatlve dis-
ease identifies the histologic characteristics of benign
breast disease that have a cancerous potential. The
term includes hyperplasias and neoplasias involving
the various segments of the ductal and lobular system,
and which mostly arise from the terminal ductal lob-
ular unit where the proliferation rate is maximal. Grad-
ing systems based on the degree of atypia and/or
hyperplasia have been developed by Wellings et al.
(15), Black and Chabon (25), Page et al. (26), and
Azzopardi (27) with which to examine the precancer-
ous potential of different histologic subcategories;
these grading systems have been reviewed by Cook
and Rohan (28). Finally, a classification system based
on the work of Page and Dupond (26, 29, 30) was
adopted at the 1985 consensus meeting of the College
of American Pathologists (31), wherein fibrocystic
breast disease lesions were divided into three groups
according to the subsequent risk of breast cancer:
nonproliferative lesions, proliferative lesions without
atypia, and atypical hyperplasias. Nonproliferative
lesions include cysts, papillary apocrine changes,
epithelial-related calcifications, mild hyperplasias (be-
tween two and four epithelial cell layers within ducts),
and fibroadenomas. Prollferatlve lesions without
atypia include moderate or florid hyperplasias (more
than four epithelial cell layers, with a tendency to
bridge or distend the ducts), intraductal papillomas,
and sclerosing adenosis. Atypical hyperplasias are
proliferative lesions that possess some but not all of
the features of carcinoma in situ; they can be divided
into two groups, atypical ductal hyperplasias and atyp-
ical lobular hyperplasias. Proliferative lesions without
atypia and atypical hyperplasia are termed prolifera-
tive diseases.
Hughes et al. (32) developed the concept of aberra-
tions of normal development and involution as a clas-
sification framework for benign breast disease based
on pathogenesis. For each period of breast develop-
ment linked to reproductive life, both normal breast
changes and associated possible aberrations of devel-
opment (aberrations which lead first to benign breast
"disorder" and finally to benign breast "disease") are
described. This classification system covers the whole
spectrum of benign breast disease conditions. Accord-
ingly, a fibroadenoma develops from a single lobule as
a result of lobular hyperplasia; it is classified as a
benign breast "disorder" or, if its size exceeds 5 cm, as
a benign breast "disease" (giant fibroadenoma). The
changes usually linked to fibrocystic disease (e.g.,
cysts, sclerosing adenosis, and simple hyperplasias)
are aberrations of involution and are classified as
benign breast "disorders." At the end of the spectrum,
atypical and lobular hyperplasias are classified as be-
nign breast "diseases."
Frequency of benign breast disease
Estimating the incidence of benign breast disease in
the general population is difficult, because it is not a
life-threatening condition and it does not necessarily
come to medical attention. Women who are diagnosed
and receive medical care are therefore a selected sub-
set of all cases. Thus, the actual detection rate is not
known and can only be approximated by comparing
the prevalence rates of benign breast disease obtained
from autopsy studies with the cumulative incidence
rates from cohort studies.
In a review of eight autopsy series performed be-
tween 1919 and 1957 (Davis et al. (33)), the preva-
lence rate of fibrocystic breast disease (defined as
macrocysts, microcysts, or epithelial hyperplasia)
among women who, during their lifetimes, had no
symptoms of benign breast disease was 58.5 percent
(424 cases/725 autopsies). These early studies were
consistent with the results of 12 other autopsy studies
published since 1937 (13, 34-44). In two more recent
series reported by Nielsen et al. (40) and Bartow et al.
(43), the prevalence of cysts was 54 percent and 61
percent, respectively, in Caucasian subjects. The prev-
alence of fibroadenoma was reported in four studies
(34, 41, 43,44), and it varied, in the studies performed
after 1980, from 15 percent (41) to 23 percent (44). It
is noteworthy that the prevalence of fibroadenoma
may be higher in black women than in white women
(45). Thus, about one out of every two women may
develop some degree of fibrocystic breast disease dur-
ing her lifetime, and one out of every five women may
develop fibroadenoma. These figures can be con-
trasted with the incidence rates computed from the
cohort studies described below.
Seven cohort studies published between 1976 and
1986 examined the incidence of benign breast disease;
five of these studies included only cases confirmed by
biopsy (46-50), and two compared rates of biopsied
and unbiopsied symptomatic disease (51, 52). The
Epidemiol Rev Vol. 19, No. 2, 1997
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age-specific incidence of biopsy-proven fibrocystic
breast disease or fibroadenoma was relatively consis-
tent across these studies.
Four comparable studies (46, 47, 49, 50) were
pooled notwithstanding heterogeneous designs: The
first study reported hospitalization rates in a cohort of
67,500 women (46); the second was a case-control
study based on a population of 485,000 women (47);
the third reported on an Australian population-based
case series (49); and the fourth reported on hospital-
ization rates of fibrocystic breast disease in a cohort of
menopausal members of a health cooperative (50).
Age-specific incidence rates are shown in figure 2.
The incidence rate per 100,000 woman-years of fibro-
cystic breast disease increases progressively from 137
at ages 25-29 years to 411 at ages 40-44 years and to
387 at ages 45-49 years, and then decreases regularly.
The incidence of fibroadenoma peaks at 115 at ages
20-24 years, decreases regularly until the ages of
45-49 years, and remains close to 5 for women of
older ages. The cumulative incidence of biopsy-
proven fibrocystic breast disease before the age of 65
years in these four studies was 8.8 percent; the corre-
sponding cumulative incidence of fibroadenoma was
2.2 percent. Thus, compared with autopsy studies,
only 10-20 percent of benign breast disease cases are
histologically diagnosed. Epidemiologic studies may
thus be focusing on the most severe forms of disease.
FACTORS ASSOCIATED WITH BENIGN
BREAST DISEASE
For the analysis of risk factors, benign breast disease
was separated into two subgroups, fibrocystic breast
disease and fibroadenoma. Fibroadenoma represents
the smaller subgroup, even though it is the most com-
mon form of benign breast disease in women aged less
than 30 years. Two studies included only fibroade-
noma: Canny et al. (53) conducted a hospital-based
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FIGURE 2. Incidence rates of fibrocystic breast disease and fibro-
adenoma, by age group.
case-control study, and Yu et al. (54) used two types of
controls, negative breast biopsy controls and popula-
tion controls. The other studies that separated fibroad-
enoma from fibrocystic breast disease comprised one
cohort study (46), one cohort-nested case-control
study (51), one screening-based case-control study
(55), two population-based case-control studies (47,
56), and 13 hospital-based case-control studies (49,
57-68). Studies in which the analysis of fibroadeno-
mas was not conducted separately usually were con-
cerned mostly with fibrocystic breast disease; these
studies are listed in table 1, but their findings are not
considered in our review, because mixing the two
pathologic entities confuses rather than clarifies the
search for their specific etiologies.
Age at menarche
Age at menarche is not associated with either fibro-
cystic breast disease or fibroadenoma. This association
has only been assessed in case-control studies, none of
which have suggested that age at menarche influences
the subsequent risk of benign breast disease (46, 47,
51, 52, 54, 58, 59, 61, 69-72).
Age at menopause
Age at menopause may possibly be related to fibro-
cystic breast disease but not to fibroadenoma. The
evidence in favor of an increased risk of fibrocystic
breast disease with later age at natural menopause
comes from four hospital-based studies (58-60, 70)
and two population-based case-control studies (47,
73). Cole et al. (47) reported the relative risks to be 1.4
and 3.0 for ages at menopause of 49-51 and >52
years, respectively, relative to ages at menopause of
<49 years (p for trend = 0.0005). Studies with more
refined histologic definitions of benign breast disease
(48, 69, 71) found no association.
Nulliparity
Nulliparous women may be at increased risk of
fibrocystic breast disease but not of fibroadenoma.
One hospital-based case-control study (57) and one
cohort study (52) found an increased risk of fibrocystic
breast disease for nulliparous versus parous women. In
the study by Cole et al. (47), this positive association
was restricted to women under 40 years of age (rela-
tive risk (RR) = 2.2, 95 percent confidence interval
(CI) 1.4-3.6). Studies generally showed no associa-
tion of nulliparity with fibroadenoma (56, 58, 59, 61).
Multiparity
A higher parity may be protective against fibrocys-
tic breast disease but not against fibroadenoma. In a
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nested case-control study (72), the relative risk was 0.5
(95 percent CI 0.3-0.8) for having five or more births
versus one or two births. Ory et al. (46) found that
the age-standardized hospitalization rates per 1,000
person-years were 5.1 for nulliparae versus 2.4 for
women with parity >5 . This protective effect was,
however, absent (69) or not statistically significant
(71) in studies using a more refined histologic defini-
tion. The association of fibroadenoma with parity has
not received much attention, and the limited available
data are inconsistent: Yu et al. (54) found a protective
effect for fibroadenoma using population controls but
not when using biopsy controls.
Age at first live birth
Findings relating late age at first live birth to fibro-
cystic breast disease are inconsistent. A positive asso-
ciation with fibrocystic breast disease was observed
only in hospital-based case-control studies (59, 60,
69). Pastides et al. (69) found a relative risk of fibro-
cystic breast disease of 1.7 (95 percent CI 1.2-2.4) for
each 5-year increase in age at first birth among women
aged <45 years, but this association was not supported
by population-based case-control studies (47, 56, 73)
nor by cohort studies (46, 72). Reported findings of
fibroadenoma with age at first live birth have been
consistently negative (46, 47, 54, 56-61).
Breastfeeding
Studies which examined the relation of ever breast-
feeding with benign breast disease failed to show an
association with either fibrocystic breast disease or
fibroadenoma (52, 54, 56, 57, 69).
Overall, the most salient findings related to repro-
ductive and menstrual history are that being parous,
being multiparous, and being young at natural meno-
pause may protect against fibrocystic breast disease.
The risk of fibroadenoma does not appear to be influ-
enced by reproductive factors. Age at menarche, age at
first live birth (even after adjustment for the total
number of live births), and breastfeeding do not seem
to be related to either fibrocystic breast disease or
fibroadenoma. Results by degree of atypia were not
fully consistent with this conclusion, but studies were
few and did not systematically include all reproductive
variables.
Education
Studies in which the compared groups were not
matched on a socioeconomic variable (56, 61, 69, 72,
74) showed that a higher level of education was pos-
itively related to fibrocystic breast disease. Hsieh et al.
(72) found a relative risk of 1.07 (95 percent CI
1.01-1.14) for each additional 1 year of education.
Nomura et al. (56) reported a relative risk of 1.8 {p <
0.05) for S:13 years versus <11 years of education.
There was, however, no difference by degree of atypia
(69, 72). Education has not been shown to be a risk
factor for fibroadenoma (56, 61).
Socioeconomic status
In studies that compared groups using higher socio-
economic status as a risk factor, most (47, 49, 51) but
not all (56, 61) found it to be positively associated
with fibrocystic breast disease. In the study by Brinton
et al. (51), risks for social classes 2, 3, and 4 relative
to social class 1 (highest) were, respectively, 0.71,
0.47, and 0.82 (p for trend < 0.05). In contrast to what
was observed for education, fibroadenoma was asso-
ciated with higher socioeconomic status in one nested
case-control study (51) and in one hospital-based case-
control study (57), while other studies showed no
significance (56) or no association (47).
Race
In 1981, Ernster (1) noted that there was a lack of
data about race/ethnicity and benign breast disease.
The situation has not dramatically changed since that
time. The lack of relevant data stems from the fact that
many studies of benign breast disease only include
white women or match controls to cases on the basis of
race (e.g., Fasal and Paffenbarger (75)). No associa-
tion has been found between race and degree of atypia
(69) or between race and histopathologic components
of fibrocystic breast disease (70).
Overall, both higher education or socioeconomic
status are more consistently related to fibrocystic
breast disease than to fibroadenoma. These positive
associations have been attributed to selection bias,
because women with benign breast disease who
consult a physician and undergo breast biopsy are
more likely to come from a higher socioeconomic
level (see the section "Potential biases" below). How-
ever, confounding by other variables known to be
associated with socioeconomic status and fibrocystic
disease, such as parity and obesity, has not been ruled
out. The effect of race on benign breast disease cannot
be assessed with the available evidence.
Family history of breast cancer
A family history of maternal breast cancer has not
been found to be related to fibrocystic breast disease,
degree of atypia, or fibroadenoma in most hospital-
based studies (61, 71) and population-based case-
control studies (56, 73), nor in a nested case-control
study (72). Pastides et al. (69), however, found a
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relative risk of 2.8 (95 percent CI 1.5-5.3) for fibro-
cystic breast disease for a history of breast cancer in a
mother or a sister of the case.
The possibility that the relation between obesity and
benign breast disease is due to detection bias is dis-
cussed below (see "Potential biases").
Obesity
Of all the risk factors reviewed, obesity had the
strongest and most consistent association with both
fibroadenoma and fibrocystic breast disease. Results
of all of the studies reviewed are consistent in finding
a protective effect, even though obesity was defined in
a variety of ways, e.g., according to current or past
body mass index (kg/m2), highest-ever body mass
index, weight, skinfold thickness, and breast size. A
strong protective effect of obesity for fibroadenoma
appeared in five studies (47, 48, 51, 54, 61) out of six
(only the study by Parazzini et al. (60) did not show
this strong protective effect). As is shown in table 2, a
body mass index over the cutoff value for overweight
(25 kg/m2) more than halved the risk of fibroadenoma
when cases were compared with either population
controls or biopsy controls (54). This same study was
unique in finding that fibrocystic breast disease cases
had a lower body mass index than did both types of
controls (76), in contrast with nine studies of fibrocys-
tic breast disease (47, 48, 51, 52, 69, 74, 77-79) that
showed a protective effect of obesity. In a nested
case-control study conducted in the United Kingdom,
Brinton et al. (51) found similar relative risks for
fibrocystic breast disease and body mass index as
those observed by Yu et al. (54) for fibroadenoma
(table 2). It is not possible to determine meaningfully
whether the inverse association differs according to
menopausal status, since only two studies (47, 71)
separated premenopausal women from postmeno-
pausal women. The one study comprising only post-
menopausal women found no effect (71). Cole et al.
(47) found a protective effect of obesity for fibrocystic
breast disease and fibroadenoma that was similar in all
age groups. No interaction with degree of atypia has
been reported.
Oral contraceptives
Several studies have found that oral contraceptive
use has a protective effect on the risk of fibrocystic
breast disease. Strong evidence is provided by the
relation of fibrocystic breast disease to duration of oral
contraceptive use found in many hospital-based case-
control studies (46, 57, 58, 61, 62, 80, 81) and in all of
the cohort studies (51, 82, 83). As is shown in table 3,
the risk of fibrocystic breast disease declined with
longer duration of oral contraceptive use in all of the
tabulated studies. There are indications that the pro-
tective effect of duration of oral contraceptive use may
be stronger in severe atypias (81, 83, 84).
Other evidence seems, however, to contradict a pos-
sible protective effect of oral contraceptive use for
fibrocystic breast disease. First, trends of increased
protection with longer duration of oral contraceptive
use have usually been reported relative to women who
have never used oral contraceptives. These trends are
much weaker when computed relative to short-term
oral contraceptive use, as shown in table 3. For exam-
ple, Canny et al. (53) found that the trend became
statistically nonsignificant when computed among oral
contraceptive users only. Second, two reports from the
same carefully designed case-control study with bi-
opsy controls (85, 86) found no association between a
longer duration of oral contraceptive use and risk of
fibrocystic breast disease in premenopausal women.
Third, the reported association of fibrocystic breast
disease with ever or current use of oral contraceptives
is inconsistent. In contrast with the duration of oral
contraceptive use, most studies failed to find a protec-
tive effect of ever use of oral contraceptives for fibro-
cystic breast disease or fibroadenoma (with the notable
exceptions of two cohort-based studies (51, 83)). Cur-
rent oral contraceptive use has been less extensively
TABLE 2. Association (relative risks) of body mass index and fibroadenoma or fibrocystic breast
disease in two studies
Histologic type and
study (reference no.)
Fibroadenoma
Yu et al. (54)
Yu et al. (54)
Brinton etal. (51)
Fibrocystic breast disease
Brinton etal. (51)
Control
type
Population
Biopsy
*
*
<21
1.0
1.0
1.0
1.0
Body mass index (kg/m2)
21-22
1.0
0.8
0.5
0.9
23-24
0.7
0.5
0.3
0.7
£25
0.4
0.4
0.2
0.7
*Oxford Family Planning Association, nested case-control study.
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TABLE 3. Association (relative
control studies
Study
(reference no.)
 < 1
risks)
<2
of oral contraceptive use and fibrocystic breast disease in three cohort and
Years of oral contraceptive use
1-2 2 >2 2-5 3-4 4 5-6 £5 6 7-8
two
8
case-
29
Cohort
Brinton etal. (51)
Hsieh et al. (83)
Ory et al. (46)
1.0
1.0
1.0
0.7
0.6
0.8 0.4
Case-control
Canny et al. (53) 1.0
Sartwell et al. (58) 1.0
0.7
0.7
0.6
1.2
0.4
0.6
0.5 0.3
1.2
0.3
0.4
0.2
0.6 0.6
investigated than ever use or duration of use. No study
showed an increased risk, and two studies showed a
protective effect for fibrocystic breast disease or fibro-
adenoma (51, 63). The inconsistency between duration
of use and ever or current use may mean that at least
1 year of oral contraceptive use is necessary to confer
a protective effect. In ever or current users, the pro-
tective effect may thus be diluted by the prevalence of
a large number of short-term users among controls.
Finally, Fechner (87) showed no differences in the
histologic features of fibrocystic breast disease be-
tween 25 users and 25 nonusers of oral contraceptives.
Similar negative findings were reported by others (88,
89).
The situation for fibroadenoma is quite similar to
that for fibrocystic breast disease, i.e., a longer dura-
tion of oral contraceptive use appears to be protective
against fibroadenoma (46, 51, 53). Kelsey et al. (62)
found a strong protective effect (RR = 0.1, 95 percent
CI 0.0-0.7) in women who used oral contraceptives
for more than 5 years, whereas, to our knowledge, no
epidemiologic study has showed a deleterious effect.
Case series comparing the histologic features of fibro-
adenoma in oral contraceptive users and nonusers do
not show clear differences (87, 90-92).
The literature on oral contraceptives use and benign
breast disease does not provide a clear picture of the
influence of the different types of oral contraceptives
on the risk of either fibrocystic breast disease or fi-
broadenoma. The results of the four studies (51, 62,
85, 93) that have addressed this issue are inconsistent.
Differences in effect related to the content of oral
contraceptives may be responsible for the heterogene-
ity found. The changing content of successive gener-
ations of oral contraceptives could also explain dis-
crepancies between older and more recent studies (85).
Several mechanisms have been proposed that could
generate a spurious protective effect of oral contracep-
tives on fibrocystic breast disease or fibroadenoma.
Hsieh et al. (83) have postulated that oral contracep-
tives may reduce the symptoms of benign breast dis-
ease and therefore hamper detection, but not affect
associated cellular pathologic developments in any
important way.
The possibility of surveillance bias is discussed be-
low (see "Potential biases").
Estrogen replacement therapy
Evidence suggests that prolonged exposure to estro-
gen replacement therapy increases the risk of fibro-
cystic breast disease. An approximate twofold in-
creased risk of fibrocystic breast disease was present
for ever use of estrogen replacement therapy in cohort
studies (50, 55) and in hospital-based case-control
studies (86, 94, 95). Duration of estrogen replacement
therapy use was consistently associated with fibrocys-
tic breast disease in the study of Jick et al. (50) (for >5
years' use, RR = 3.7, 95 percent CI 1.6-8.4; no trend
was present with longer duration of use), in the study
of Trapido et al. (55), and in the hospital-based case-
control studies (86, 94, 95). Berkowitz et al. (94)
found a relative risk of 4.3 (95 percent CI 2.2-12.3)
for > 10 years of estrogen replacement therapy use in
menopausal women. Important results are summarized
in table 4.
TABLE 4. Association (relative risks) of estrogen replacement therapy use and fibrocystic breast
disease in three studies
Study
(reference no.)
Nomura and Comstock (125)
Trapido et al. (55)
Pastides et al. (95)
S1
1.0
<2
1.0
1.0
Duration of estrogen replacement therapy use in years
1-2 1-4 2-4 23 5-9
0.7 1.4
1.2
1.6 3.6
£10
3.5
1.4
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On the other hand, some studies showed no effect
for ever use (58, 60, 61) or current use (61, 94, 96) of
estrogen replacement therapy on fibrocystic breast dis-
ease. Bright et al. (77) found a protective effect (odds
ratio = 0.4, 95 percent CI 0.1-0.9).
The only study (86) which stratified by histologic
degree of atypia found no difference in risk for ever
use or a 5 years' use of estrogen replacement therapy
across the various degrees of atypia. Fechner et al.
(97), in a histopathologic study, did not observe any
significant difference in the frequency of epithelial
hyperplasia or type of lesions between two groups,
each of which consisted of 41 women, who had re-
ceived or not received estrogen replacement therapy.
Although fibroadenoma is predominantly a pre-
menopausal disease, its relation to estrogen replace-
ment therapy has been studied because of concerns
that this type of therapy could stop the involution of
the mammary gland and increase the prevalence of
fibroadenoma in postmenopausal women. The study
by Canny et al. (53), in contrast to five other studies
(54, 55, 58, 60, 61), found an elevated risk in women
aged >45 years (RR = 3.1, 95 percent CI 1.1-9.4) for
ever use of estrogen replacement therapy and for use
of >1 year's duration (RR = 3.7, p for trend = 0.01).
Women who receive estrogen replacement therapy
may be more likely to undergo medical breast exam-
ination. This possible bias is discussed below.
Smoking
Most reports show no substantial effect of ever,
former, or current smoking on either fibrocystic breast
disease or fibroadenoma, even across different atypia
grades (54, 56, 64, 65, 98-100); however, Berkowitz
et al. (64, 95) found protective effects, and Nomura
and Comstock (56) found deleterious effects.
Diet
Studies on the effect of diet are relatively recent, and
therefore use more comparable definitions of benign
breast disease. Results are contradictory, and no clear
patterns have emerged.
Rohan et al. (101) reported that a higher daily intake
of energy was associated positively with benign epi-
thelial proliferative disease when cases were compared
with biopsy controls (highest versus lowest quintile of
total calories: RR = 1.6, 95 percent CI 0.9-3.0; p for
trend = 0.04) and associated inversely when cases
were compared with community controls (RR = 0.5,
95 percent CI 0.3-0.9; p for trend = 0.02). Lubin et al.
(102) showed a positive association of higher intake of
all foods with fibrocystic breast disease atypias of
grade >3 using hospital and neighborhood controls.
Ingram et al. (103) found no association of total en-
ergy intake with epithelial hyperplasia, neither did
Vobecky et al. (104), regardless of whether clinical or
biopsied fibrocystic breast disease was examined.
A relative risk of about 0.5 was reported by Ingram
et al. (103) for intake of various food items, such as
sugar, eggs, chicken, and seafood, and by Hislop et al.
(79) for frequent consumption of green vegetables. A
similar conclusion was reached by Simard et al. (74)
for patients who ate less meat, offal, and cooked
vegetables.
Total fat intake has been variably associated with
increased (101, 103, 104), decreased (101), or un-
changed (103) risk of fibrocystic breast disease across
studies. However, Lubin et al. (102), when combining
both hospital and neighborhood controls, found a rel-
ative risk of 7.6 (95 percent CI 1.4-40.2) for severe
atypias associated with food items containing more
than 10 percent fat.
Baghurst et al. (105), using hospital controls, found
a reduced risk of benign epithelial proliferative disease
for the highest versus lowest quintile of fiber ingestion
(RR = 0.5, 95 percent CI 0.2-0.8; p for trend = 0.02),
especially in premenopausal women. A protective ef-
fect (RR = 0.6) was also present with community
controls but was not statistically significant. In con-
trast, Rohan et al. (101), employing the same study
population as Baghurst et al. (105) but using incident
and prevalent cases instead of only incident cases,
found no association between fiber and benign epithe-
lial proliferative disease with hospital controls and a
protective effect with community controls {p for trend
across quintiles of fiber intake = 0.04). Another
population-based case-control study (103) showed no
association of fiber with epithelial hyperplasia or fi-
brocystic breast disease without hyperplasia, and a
screening-based case-control study (104) found an in-
creased risk of benign epithelial proliferative disease
for women aged >50 years.
No consistent association between benign breast
disease and use of vitamins has been observed (71, 79,
101, 103-105). Retinol and /3-carotene were found to
be protective by Rohan et al. (101) using community
controls, but not with biopsy controls; this is contrary
to findings in the studies by London et al. (71) and
Ingram et al. (103). Vitamin E has long been used in
the treatment of benign breast disease (106); although
an intervention study of 26 patients reported a remis-
sion rate of 85 percent (107), later studies with a
double-blind design conducted by the same group
(108) and by Ernster et al. (109) failed to show a
significant improvement of fibrocystic breast disease
after treatment with vitamin E (compared with a
placebo).
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The effect of alcohol consumption on benign epi-
thelial proliferative disease has been investigated in
detail by Rohan et al. (76). There was no indication of
an association using either biopsy controls (RR = 1.0)
or population controls (RR = 0.9), even after stratifi-
cation for degree of atypia.
Methylxanthine consumption
After a decade of intense investigation into a possi-
ble deleterious effect of methylxanthines (caffeine,
theobromine, and theophylline) on fibrocystic breast
disease, there is no strong support for an association.
Reports on uncontrolled and nonrandomized case se-
ries published in 1979 and 1981 (9-11) showed that
caffeine restriction dramatically improved benign
breast disease symptomatology. The etiologic hypoth-
esis was that methylxanthines present in coffee inhib-
ited cyclic adenosine monophosphate (AMP) and gua-
nylic acid (GMP) phosphodiesterases, and activated a
protein kinase. This resulted in an overproduction of
fibrous tissue and cystic fluid, leading to benign breast
disease. These first results were supported by some
case-control studies (66, 67) but not all (37, 110). The
strongest counter-evidence, however, came from stud-
ies that measured the amount of exposure in milli-
grams of methylxanthines (68, 111, 112); these studies
found no consistent association with fibrocystic breast
disease across populations or across control groups
(112). Methylxanthine consumption has not been
found to be related to fibroadenoma (66-68).
POTENTIAL BIASES
Epidemiologic studies of benign breast disease re-
quire special attention to guard against the occurrence
of selection (including detection and surveillance)
bias, misclassification, and incidence/prevalence
biases.
Selection
In the "Methods" section, we estimated that only
10-20 percent of benign breast disease cases are his-
tologically diagnosed. Study validity will therefore
be compromised if the selection process differs
across compared groups (case-control or exposed-
nonexposed) because of differential access to medical
care (selection bias), the diagnostic process (detection
bias), or intensity of medical care (surveillance bias).
The observed association between high socioeco-
nomic status and benign breast disease may be due to
selection bias. Women with more education or higher
socioeconomic status may more likely consult a phy-
sician for benign disorders, or examine their breasts
more frequently, than women from lower social
groups. This association between education or income
variables and risk of benign breast disease may persist
even when cases are restricted to histologically con-
firmed benign breast disease since similar differential
selection process according to social factors may occur
for access to biopsy.
The possibility of detection bias has been raised as
a possible explanation for the inverse relation of obe-
sity to benign breast disease; nodules may be easier to
detect in thin women (with less fat in their breasts)
than in obese women. It is of note that the anthropo-
metric basis of this detection bias is still elusive, since
it has not been established that obese women have
larger breasts than nonobese women. Sasano et al.
(39), in an autopsy series, found that body mass index
was positively correlated with total mammary volume
(fat and gland) but not with glandular volume. Hislop
et al. (52) showed that body mass index and breast size
were independently associated with benign breast dis-
ease, breast size being the major factor before age 30
years and obesity after age 30 years.
The mechanism leading to uncompensated surveil-
lance bias is not straightforward; i.e., increased med-
ical surveillance of women taking estrogen replace-
ment therapy may explain (totally or in part) why
prolonged exposure to this therapy increases the risk
of fibrocystic breast disease. On the other hand, the
inverse trend between duration of oral contraceptive
use and risk of fibrocystic breast disease could also be
due to surveillance bias if physicians withhold oral
contraceptives from women with benign breast dis-
ease. Indeed, it was shown in 1977 (4) that one third of
physicians thought that benign breast disease was a
contraindication to prescribing oral contraceptives,
and that many women with benign breast disease
stopped using oral contraceptives following medical
advice.
Although the potential for selection bias is large, for
the reasons just described, the conclusions presented
here were strongly influenced by the results of studies
that seriously attempted to prevent selection bias by
comparing groups that had undergone a similar selec-
tion process. In an Australian case-control study (54,
76, 98, 101, 105, 112), for example, population con-
trols were matched to cases by socioeconomic grading
of area of residence. It was reassuring to note on
grounds of comparability that breast self-examination
was practiced with equal frequency in cases and in
both types of controls (a matched population control
group and an unmatched biopsy control group) (54).
Similarly, detection bias can be prevented if the
likelihood of detection of the lesion is similar across
the compared groups. In that Australian study (54, 76,
98, 101, 105, 112), two control groups were chosen,
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one of which comprised women who had undergone
breast biopsy in the same way as had the cases but
whose breasts were histologically normal. It was,
therefore, important to find that the inverse association
between obesity and risk of fibroadenoma persisted
when cases were compared with biopsied controls,
since detection of the lesion might also be affected by
body mass in biopsied controls (54).
Misclassification
As in studies of breast cancer, etiologic studies of
benign breast disease can be plagued by misclassifi-
cation of exposure and by recall bias (for example, if
a woman feels an improvement or a worsening of her
clinical symptoms while using oral contraceptives, she
may recall the use of the oral contraceptives differ-
ently than would a woman without benign breast dis-
ease). In addition, because benign breast disease is
such a loosely defined pathology (as discussed previ-
ously), misclassification of disease is also a serious
concern.
Several scenarios of disease misclassification are
plausible. Controls may suffer from undetected benign
breast disease, or clinically diagnosed patients may be
classified as having benign breast disease but in reality
have normal breasts. The proportion of clinically sus-
pected benign breast disease that corresponds to phys-
iologic changes is unknown, but it could be as high as
50 percent, and this is because incidence rates of
unbiopsied benign breast disease are about twice as
high as those of biopsied benign breast disease; in the
study of oral contraceptive users by Brinton et al. (51),
incidence rates per 100,000 woman-years were 187 for
fibrocystic breast disease biopsies and 293 for clinical
nodules without biopsy, and in the study by Hislop et
al. (52), rates were 540 for biopsied disease (any
diagnosis) and 1,040 for nonbiopsied symptomatic
mastopathies.
A more subtle form of misclassification may occur
when the tissue obtained by biopsy is not representa-
tive of the pathology of the entire breast. Lesions in
the breast tissue surrounding the biopsy area may have
a different degree of atypia than the biopsied tissue.
Biopsy can also detect fibroadenoma lesions but not
adjacent fibrocystic breast disease lesions; this results
in misclassification of fibroadenoma as fibrocystic
breast disease, or vice versa.
Misclassification of disease can also result from
diagnostic inaccuracy. In a case-control study con-
ducted in Connecticut by Berkowitz et al. (85), it was
estimated that the agreement between two pathologists
reading the same biopsy slides of fibrocystic breast
disease and fibroadenoma was fair (K = 0.64) and
slightly lower than the intraobserver reliability (K =
0.79).
Using only histologically confirmed cases can limit
the extent of misclassification of disease in cases.
However, this gain in validity may be counterbalanced
by increased selection, since access to successful bi-
opsy may differ according to socioeconomic status,
obesity, etc.
In this review special attention has been given to
studies that attempted to reduce the likelihood of dis-
ease misclassification. For example, in a New Haven,
Connecticut, study (53, 64, 66, 85, 86, 94), all biopsy
slides of women with a presumptive diagnosis of fi-
brocystic breast disease were reevaluated by a pathol-
ogist, and a representative sample was then reviewed
by a second pathologist. Of 981 potential cases, 634
(65 percent) were retained as fibrocystic breast dis-
ease. Similarly, in a Boston, Massachusetts, nested
case-control study, the slides of 272 women with sus-
pected incident fibrocystic breast disease were identi-
fied for review, of which 34 (12.5 percent) had to be
excluded (72).
Temporality
Because benign breast disease is nonfatal and is
likely to remain undetected for many years, it is not
always possible to decide whether or not the lesion
preceded exposure to a possible risk factor. This phe-
nomenon may occur even in studies that exclude
women with a previous history of benign breast dis-
ease. The main advantage of cohort studies over case-
control studies when studying benign breast disease
etiology is that chances of including only those lesions
occurring after exposure are improved.
SYNTHESIS
In the conclusion of her review, Ernster (1) called
for a separation of fibroadenoma and fibrocystic breast
disease and for implementation of the new classifica-
tion for fibrocystic breast disease related to the subse-
quent risk of breast cancer. Recent studies have fol-
lowed this advice, and their results have been
reviewed here. They can be synthesized as follows.
Fibrocystic breast disease, but not fibroadenoma, is
related to a woman's reproductive history. Nullipar-
ity and late menopause may increase the risk of fibro-
cystic breast disease, while high parity may decrease
the risk. On the other hand, age at menarche, age at
first live birth, and breastfeeding are not consistently
associated with fibrocystic breast disease.
These results suggest that the probability of aberra-
tions of normal development and involution is in-
creased by a higher cellular proliferation of the breast
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epithelium (as, for example, during the second part of
the ovulatory cycle) and is decreased by factors which
slow the proliferation of breast cells (such as the
glandular differentiation occurring after a full-term
pregnancy). Thus, parity would protect against fibro-
cystic disease because parity influences full develop-
ment of the breast; late age at menopause would be
deleterious because of longer exposure to ovarian hor-
mones. The absence of an effect of age at menarche
and age at first live birth could be attributed to the age
distribution of women with the disease, that is, early
reproductive events may be too far removed in time
from the perimenopausal years, during which the in-
cidence of fibrocystic breast disease reaches its peak.
While endocrine etiology for benign breast disease
has long been suspected, as symptomatology fluctu-
ates with the menstrual cycle, it has not been demon-
strated. In their review of the endocrine based studies
of benign breast disease, Wang and Fentiman (113)
could not identify a clear or consistent pattern of
hormonal abnormalities, but this may have been due to
the heterogeneity of conditions defined as benign
breast disease. Sitruk-Ware et al. (114, 115) found that
women with benign breast disease had a lower pro-
gesterone : estradiol ratio, and this was attributed to
inadequate corpus luteum function. The identification
of a hormonal origin of benign breast disease is further
complicated by the fact that serum hormones may not
reflect the local hormonal milieu of the breast: Ernster
et al. (116) and Petrakis et al. (117) demonstrated that
levels of estradiol and estrone were markedly (5-45
times) higher in breast fluid than in serum among both
premenopausal and postmenopausal women, but these
levels did not correlate with each other. Also, breast
fluid estrogen levels do fluctuate (they are lower in
parous premenopausal women than in nulliparous pre-
menopausal women, and are positively correlated with
time since last birth or since last breastfeeding), ham-
pering the interpretation of hormonal differences be-
tween benign breast disease and normal breast fluids.
Obesity is protective against both fibroadenoma and
fibrocystic breast disease. The protective effect of
obesity is highly consistent across studies, even among
those using biopsy controls. The biologic basis of this
association may be related to the hormonal conse-
quences of obesity—as, for example, the alterations of
androgen metabolism involved in impaired ovulation
(118).
The protective effect of oral contraceptives is sus-
pected but has not been established. The protective
effect of oral contraceptives may stem from a suppres-
sion of the peak in estrogen and progesterone levels
that occurs during the second part of the menstrual
cycle. This interpretation is debatable, however, since
Anderson et al. (119) found increased cell prolifera-
tion in breast tissue adjacent to benign lesions (mostly
fibroadenomas) in nulliparous (but not parous) oral
contraceptive users, which was related to the estrogen
content of the oral contraceptives. In addition,
Williams et al. (120) showed that oral contraceptive
use was linked to a longer period of high proliferation
of epithelial cells (and a decrease in estrogen receptor
content) in normal breasts during the menstrual cycle.
It is important to know whether the risk of benign
breast disease differs according to the composition of
oral contraceptives, but more data about the effects of
different types of oral contraceptives are needed.
Estrogen replacement therapy may enhance benign
breast disease risk. An increased risk of fibrocystic
breast disease in estrogen replacement therapy recipi-
ents has been consistently found. As this observation
is also compatible with increased medical attention
among estrogen replacement therapy users, a surveil-
lance bias remains an alternate explanation.
There are no known preventable risk factors for be-
nign breast disease. Cigarette smoking, diet, and
methylxanthines have not been found to be associated
with benign breast disease in the current literature.
CONCLUSION
Endocrine factors are involved in the etiology of
benign breast disease, but their precise roles remain to
be elucidated. There are no known modifiable risk
factors for benign breast disease. The only known
protective factor, obesity, cannot be promoted because
of its other potentially deleterious effects on a wom-
an's health. The roles of oral contraceptives and
estrogen replacement therapy need to be further inves-
tigated, with special attention paid to their pharm-
aceutical content. Despite the absence of associations
in the general population, subgroup differences related
to genetic susceptibility cannot be ruled out.
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